Tesamorelin

Tesamorelin is a synthetic GHRH(1-44) analogue that stimulates pulsatile growth hormone release from the pituitary, with the downstream effect of reducing visceral adipose tissue (VAT). It is FDA-approved for HIV-associated lipodystrophy under the brand Egrifta SV [1], but as of 2026 it is not visibly listed on the SAHPRA medicines register, and no publicly documented Section 21 authorisations for tesamorelin exist in South Africa. Locally, it circulates as research-grade peptide, and JCSG.org carries Body Pharm tesamorelin for South African researchers.

This guide covers the GHRH → GH → IGF-1 → VAT pathway, dosage protocol, injection timing, side-effect profile (including glucose effects), and the regulatory reality for South African researchers. You will find how tesamorelin works at the cellular level, what the clinical evidence actually shows, how to dose and monitor it safely, and where it stands legally in South Africa.

Key Takeaways

• Tesamorelin is a GHRH analogue with FDA approval for HIV-associated lipodystrophy; it is not SAHPRA-registered in South Africa and circulates as research peptide only.
• It reduces visceral adipose tissue by triggering pulsatile endogenous GH release, preserving the body's natural feedback control unlike exogenous growth hormone.
• The clinical evidence base is confined to HIV-lipodystrophy trials (2008–2018); no large non-HIV randomised trial exists as of 2026.
• Common side effects include injection-site reactions, fluid retention, arthralgia, and modest glucose elevation in pre-diabetic individuals; IGF-1 monitoring is essential.
• Research dosing in South Africa typically sits at 1 mg/day subcutaneously at bedtime; the FDA-approved clinical dose is 2 mg/day.
• Tesamorelin is often paired with ipamorelin to amplify GH pulses through dual-receptor activation, though no large trial has tested this combination.
• Researchers must work with an HPCSA-registered clinician for baseline and periodic glucose, HbA1c, and IGF-1 testing.

What Is Tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH) that reduces visceral adipose tissue by binding pituitary GHRH receptors and stimulating the body's own pulsatile growth hormone secretion [6]. It is sold in the United States under the brand name EGRIFTA (later reformulated as EGRIFTA SV) and is FDA-approved for HIV-associated lipodystrophy [10].

The molecule is identical to endogenous GHRH(1-44) except for a trans-3-hexenoic acid group added to the N-terminus. This modification protects it from rapid degradation by dipeptidyl peptidase-4 and extends its functional activity beyond native GHRH [6].

What tesamorelin is not

Tesamorelin is not an anabolic steroid. It does not introduce exogenous growth hormone into the body. Instead, it acts upstream, prompting the pituitary to release GH in its natural pulsatile rhythm. This preserves negative feedback through somatostatin and IGF-1. That mechanism separates it from recombinant human GH (somatropin), which bypasses pituitary regulation entirely by delivering hormone directly into the bloodstream rather than triggering endogenous release.

Within the broader GHRH analogue class, the closest relative is CJC-1295, a truncated GHRH(1-29) analogue. Research protocols often pair a GHRH analogue with a ghrelin mimetic such as ipamorelin for synergistic GH release. The CJC-1295 and ipamorelin combination pen illustrates that combined approach — the two receptors converge on GH secretion through separate intracellular cascades.

In the South African context, tesamorelin is not a SAHPRA-registered medicine and circulates exclusively as a research peptide. JCSG.org carries Body Pharm tesamorelin for South African researchers.

How Tesamorelin Works: The GHRH → GH → VAT Pathway

Tesamorelin reduces visceral adipose tissue through a four-step upstream cascade:

1. It binds GHRH receptors on the anterior pituitary.
2. This triggers pulsatile endogenous growth hormone (GH) release.
3. GH drives lipolysis preferentially in visceral fat.
4. The result is sustained reductions in VAT and triglycerides without bypassing the body's own feedback control [6][17].

Step 1: GHRH receptor binding at the anterior pituitary

The trans-3-hexenoic acid-modified GHRH(1-44) molecule resists dipeptidyl peptidase-4 cleavage and binds GHRH receptors on somatotroph cells of the anterior pituitary [6]. This binding mimics endogenous hypothalamic GHRH signalling rather than introducing any exogenous hormone. The modified side chain prevents enzymatic breakdown that would otherwise occur within minutes.

Step 2: Pulsatile GH release

Receptor activation prompts the pituitary to release stored GH in its physiological pulsatile rhythm. Somatostatin tone and IGF-1 negative feedback remain intact, so peak GH concentrations are constrained by the body's own regulatory ceiling. This is the principal mechanistic distinction from recombinant somatropin, which delivers a non-pulsatile, supraphysiological GH load directly into circulation and suppresses endogenous GH secretion through feedback inhibition. The same upstream logic underpins related analogues such as CJC-1295. Tesamorelin's plasma half-life of roughly 0.6–1.1 hours produces a discrete daily pulse rather than the multi-day exposure seen with DAC-conjugated variants [13][14].

Step 3: GH-driven lipolysis in visceral fat

Circulating GH activates hormone-sensitive lipase and suppresses lipoprotein lipase activity. Visceral adipocytes show greater GH receptor density and lipolytic responsiveness than subcutaneous depots because visceral tissue is metabolically more active and responsive to hormonal signals [6]. Free fatty acids released from VAT are then oxidised or cleared hepatically, lowering circulating triglycerides.

Step 4: VAT and triglyceride reduction, with IGF-1 as the monitoring marker

In HIV-lipodystrophy trials, daily 2 mg tesamorelin produced sustained decreases in VAT and triglycerides over 52 weeks without aggravating glucose homeostasis at the group level [18][19]. IGF-1 rises predictably as a downstream marker of GH action because GH stimulates hepatic IGF-1 production. Egrifta SV prescribing information recommends periodic IGF-1 measurement, with dose interruption or discontinuation if levels persistently exceed the age- and sex-adjusted upper limit of normal [1].

South African researchers running protocols at home should pair tesamorelin use with baseline and periodic fasting glucose, HbA1c, and IGF-1 testing. This matters most in pre-diabetic individuals, where older NATAP and JAMA data flagged modest glycaemic drift [18][19]. Stacked GHRH-plus-ghrelin-mimetic protocols, such as the CJC-1295 and ipamorelin combination pen, amplify the same GH pulse but compound the monitoring burden because dual-receptor activation produces larger GH spikes and higher IGF-1 exposure.

Clinical Evidence: What the Research Shows (2008–2026)

The regulatory-grade evidence base for tesamorelin sits almost entirely in HIV-associated lipodystrophy. Three studies between 2008 and 2018 form the foundation. No large non-HIV randomised trial has been published through to 2026 [5][6].

NATAP 52-week safety extension (2008–2011)

The NATAP-reported 52-week data on daily 2 mg subcutaneous tesamorelin in HIV-positive adults with excess abdominal fat showed sustained VAT reduction and triglyceride decreases. There was no group-level worsening of fasting glucose or HbA1c over the full year [10]. A subset of participants with baseline glucose intolerance showed modest glycaemic drift — this is the origin of the standing recommendation to monitor fasting glucose and HbA1c in pre-diabetic individuals, because this subgroup demonstrated measurable increases in fasting glucose despite the absence of a group-level signal [10]. These data are pre-2023 and should be treated as foundational rather than current.

Stanley et al., JAMA 2014

Stanley and colleagues reported in JAMA that 6 months of daily 2 mg tesamorelin reduced visceral adipose tissue and hepatic fat fraction in HIV-positive adults with abdominal fat accumulation [11]. The liver-fat finding was novel beyond earlier VAT-only endpoints. The trial reinforced the IGF-1 monitoring framework later codified in Egrifta SV labelling, because sustained IGF-1 elevation above the upper limit of normal was associated with adverse effects in longer-term follow-up [11][16]. As 2014 data, the absolute numbers are now over a decade old and should be read as directional.

Adrian S, PMC 2018 mechanism review

The 2018 PMC review by Adrian and colleagues consolidated the GHRH-receptor pharmacology, pulsatile GH release, and downstream lipolytic pathway that underpins tesamorelin's VAT-selective effect [6]. It remains the most cited single mechanism reference for researchers comparing tesamorelin to CJC-1295 and other GHRH analogues. No subsequent mechanism studies have superseded its findings.

Post-2023 literature and research gaps

Post-2023 publications have not produced a phase 3 non-HIV obesity trial. A 2025 US phase 2 registry entry pairs tesamorelin with structured exercise in adults with HIV for muscle-health endpoints. The active research frontier remains inside the HIV population [5]. Small pre-2023 pilots in NAFLD and impaired glucose tolerance exist but have not been replicated at scale — funding and regulatory interest remain concentrated on the HIV indication where the drug holds FDA approval.

Any use in non-HIV South African adults for body recomposition, including stacked protocols using a CJC-1295 and ipamorelin combination pen, is off-label and rests on extrapolation from HIV-lipodystrophy data rather than dedicated trials.

Tesamorelin Benefits for Fat Loss and Metabolic Health

Tesamorelin's documented benefits cluster around five evidence-supported endpoints, all derived from HIV-lipodystrophy trials rather than general-population obesity studies:

• Visceral adipose tissue (VAT) reduction
• Triglyceride lowering
• Modest liver fat reduction
• Lean mass preservation
• Absence of androgenic activity

The strength of this evidence is regulatory-grade for HIV lipodystrophy and extrapolative for everyone else.

What the HIV-lipodystrophy trials actually show

VAT reduction is the primary studied outcome. Pooled phase 3 data underpinning Egrifta SV labelling reported roughly 15–18% VAT reduction over 26 weeks at 2 mg daily in HIV-positive adults with abdominal fat accumulation [2][6]. Triglyceride reductions were sustained at 52 weeks in the NATAP-reported extension cohort. The absolute magnitude was modest and tracked with VAT change because triglyceride clearance depends on the free fatty acids released from lipolysed visceral fat [13].

Stanley et al. (JAMA 2014) added the liver-fat finding: a measurable reduction in hepatic fat fraction independent of total body weight change [11].

Lean mass is preserved rather than gained. The GH pulse driven by GHRH receptor activation supports nitrogen retention without the supraphysiological IGF-1 spikes seen with exogenous GH. This is why tesamorelin is framed as recomposition-adjacent rather than anabolic [6].

What tesamorelin does not do

Tesamorelin is not a subcutaneous fat-loss drug. The lipolytic effect is preferential for visceral depots because visceral adipocytes express higher GH receptor density than subcutaneous tissue. Trial participants did not show meaningful reductions in subcutaneous abdominal fat [2]. It carries no direct androgen-receptor activity, so the side-effect profile diverges sharply from anabolic steroids — the trade-off is glucose metabolism rather than virilisation [13][14].

Off-label fat-loss use in South African adults

For non-HIV users, including those running tesamorelin alone or stacking it with a ghrelin mimetic such as ipamorelin via a CJC-1295 and ipamorelin combination pen, the benefit claims rest entirely on extrapolation. No 2024–2026 phase 3 trial has tested tesamorelin in metabolically healthy or simply overweight adults [1]. Researchers comparing pulsatile versus longer-acting GHRH exposure should read the tesamorelin data alongside the CJC-1295 pharmacokinetic profile rather than treating the two as interchangeable — their half-lives and receptor occupancy patterns produce different GH secretion profiles.

Tesamorelin Dosage Guide: Units, Timing, and Reconstitution

The most commonly cited research dose for tesamorelin is 1 mg subcutaneously per evening. This equates to 25 units on a U-100 insulin syringe when a 5 mg vial is reconstituted with 2.5 mL of bacteriostatic water. The FDA-approved clinical dose for HIV-associated lipodystrophy is higher: 2 mg/day subcutaneous, per the EGRIFTA SV prescribing information [1].

Clinical versus research dosing

EGRIFTA SV's label specifies 2 mg subcutaneously once daily into the abdomen. IGF-1 is monitored periodically and dose interruption is considered if IGF-1 persistently exceeds the age- and sex-adjusted upper limit of normal (ULN) [1]. Research-context protocols circulating in South African peptide communities frequently sit at 1 mg/day, half the licensed dose. The rationale is that VAT reduction signals appear at lower exposures in non-HIV users — an extrapolation with no 2024–2026 trial backing, because no dose-ranging study in non-HIV populations has been published.

Injection timing

Bedtime subcutaneous administration is the convention. It is timed to coincide with the body's natural nocturnal GH pulse so the GHRH receptor stimulus stacks with endogenous secretion rather than fighting daytime somatostatin tone. Somatostatin levels are lowest during sleep and highest during waking hours [6]. Rotate sites across the lower abdomen to limit local lipoatrophy, because repeated injections at the same site can trigger lipodystrophy (fat loss) or lipohypertrophy (fat accumulation).

Reconstitution

Draw 2.5 mL of bacteriostatic water slowly down the inside wall of a 5 mg tesamorelin vial. Never apply water directly onto the lyophilised powder — direct contact can cause foaming and peptide denaturation. Swirl gently until clear. Do not shake, as vigorous agitation can denature the peptide. Refrigerate at 2–8 °C after reconstitution and discard per the stability window on the vendor's certificate of analysis.

At this dilution, 0.1 mL (10 units on a U-100 insulin syringe) delivers 200 µg. Therefore, 25 units delivers 500 µg and 50 units delivers 1 mg. Check your own arithmetic against the vial size you actually hold.

Cycle length

Published HIV-lipodystrophy trials ran 12 to 26 weeks of continuous daily dosing before VAT endpoints were assessed [1]. Researchers comparing pulsatile GHRH exposure with longer-acting analogues should read this alongside the CJC-1295 half-life data rather than assuming equivalent cycle structures, because the longer half-life of DAC-conjugated CJC-1295 may require different cycle lengths to achieve comparable IGF-1 exposure.

Dosage, cycle length, and monitoring must be determined by a qualified medical practitioner registered with the HPCSA. Nothing above constitutes a prescription or clinical instruction.

Tesamorelin + Ipamorelin: Combination Protocol Overview

Tesamorelin is paired with ipamorelin to stack two distinct GH-releasing mechanisms in a single bedtime injection. Tesamorelin activates the GHRH receptor on pituitary somatotrophs. Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a) as a selective ghrelin mimetic. Because the two receptors converge on GH release through separate intracellular cascades, co-administration produces a larger amplitude GH pulse than either peptide alone — without the cortisol and prolactin spill-over seen with older secretagogues like GHRP-6, because ipamorelin shows greater selectivity for GHS-R1a over other ghrelin-receptor subtypes.

Endogenous GH is already pulsing during slow-wave sleep and somatostatin tone is at its diurnal low. A dual-receptor stimulus rides that wave rather than fighting daytime inhibition.

How it sits next to CJC-1295

Researchers comparing pulsatile versus sustained GHRH exposure usually contrast tesamorelin with CJC-1295, the other commonly cited GHRH analogue. CJC-1295 without DAC behaves similarly to tesamorelin on a per-pulse basis — both are short-acting GHRH(1-29) or GHRH(1-44) analogues. The DAC-conjugated version pushes towards quasi-continuous receptor occupancy because albumin binding extends the half-life to 5–8 days [6]. Pre-mixed combination products such as the CJC-1295 and ipamorelin pen exist to deliver the dual-receptor stack in one injection. The tesamorelin + ipamorelin pairing follows the same design logic with a different GHRH backbone.

Evidence caveat

No large randomised trial has tested the tesamorelin + ipamorelin combination against tesamorelin monotherapy for VAT reduction, IGF-1 trajectory, or glucose endpoints. The available evidence is clinical and observational, drawn from prescribing practice in compounded peptide settings rather than registry-grade randomised controlled trials. Treat any combination protocol as off-label. Have IGF-1 monitored against the upper limit of normal as the Egrifta SV label advises for tesamorelin alone [18].

Tesamorelin Side Effects and Safety Profile

Tesamorelin is generally well tolerated in clinical trials. The most common adverse effects are mild injection-site reactions, fluid retention, and arthralgia. Serious risks centre on IGF-1 elevation, glucose dysregulation in susceptible individuals, and contraindication in active malignancy or pregnancy [5][7]. The 52-week HIV-lipodystrophy data reported sustained VAT and triglyceride reductions without aggravating fasting glucose at the group level [5].

The reproducible side-effect cluster from the Egrifta SV label and HIV-lipodystrophy trials includes:

• Injection-site reactions — erythema, pain, pruritus, swelling, or haematoma at the abdominal injection point. These are usually self-limiting within 24–48 hours [7].
• Fluid retention and peripheral oedema — most pronounced in the first 4–8 weeks as IGF-1 rises. IGF-1 increases renal sodium reabsorption and vascular permeability; this often settles as the body adapts [7].
• Arthralgia and myalgia — joint and muscle aching consistent with the GH-axis response. The effect is dose-dependent in pattern because GH and IGF-1 increase collagen turnover and fluid shifts in connective tissue [7].
• Paraesthesia and carpal tunnel-type symptoms — reported in a minority, reflecting elevated GH/IGF-1 signalling. Increased tissue fluid and collagen deposition can compress peripheral nerves [7].
• IGF-1 elevation above the age- and sex-adjusted upper limit of normal — the label advises dose interruption or discontinuation if persistent, because sustained supraphysiological IGF-1 is associated with increased cancer risk in observational data [7].
• Glucose metabolism changes — modest increases in fasting glucose and HbA1c in a subset of HIV patients with baseline glucose intolerance. GH is diabetogenic and antagonises insulin signalling. No large signal for new-onset diabetes appeared in the 52-week NATAP data [5][6].
• Hypersensitivity reactions — rare but documented, including rash and urticaria [7].

Contraindications and monitoring

Tesamorelin is contraindicated in active malignancy (GH/IGF-1 signalling is mitogenic and can accelerate tumour growth), disrupted hypothalamic-pituitary axis from surgery, radiation or trauma, and pregnancy [7]. Baseline and periodic IGF-1, fasting glucose, and HbA1c are the minimum sensible panel. The Egrifta SV label specifically directs measuring IGF-1 periodically and acting on sustained ULN exceedance because IGF-1 is the most reliable marker of GH action and its elevation predicts adverse effects [7]. Pre-diabetic researchers should weigh the glucose signal carefully — the evidence base remains the older HIV-lipodystrophy cohorts rather than non-HIV metabolic-syndrome RCTs [5][6].

Researcher warning. Tesamorelin is not SAHPRA-registered as a finished medicine in South Africa as of 2026, and research-peptide vials are not quality-controlled to pharmaceutical standards. Pair any self-directed protocol with a clinician who can order bloods and interpret them against the CJC-1295 and broader GHRH-analogue literature. For research use only.

Tesamorelin in South Africa: Regulatory Status (2026)

Tesamorelin is not registered as a medicine on the SAHPRA database as of May 2026. It cannot lawfully be marketed, prescribed, or dispensed as a finished pharmaceutical product in South Africa because the Medicines and Related Substances Act (Act 101 of 1965) requires all medicines for human use to be registered or authorised by SAHPRA. The South African Health Products Regulatory Authority (SAHPRA), not the US FDA, is the relevant authority for medicines registration locally [5]. EGRIFTA SV, the branded tesamorelin formulation from Theratechnologies, holds FDA approval in the United States for HIV-associated lipodystrophy but has no equivalent South African registration [4][10].

Section 21 access under Act 101 of 1965

Section 21 of the Medicines and Related Substances Act (Act 101 of 1965) permits SAHPRA to authorise the use of an unregistered medicine for a specific patient or institution where a clinical need is demonstrated and no registered alternative exists. The treating practitioner submits a motivated application, and SAHPRA decides on a named-patient or named-institution basis [5]. There is no public record in 2024–2026 of any South African hospital, endocrinology practice, or compounding pharmacy receiving Section 21 authorisation specifically for tesamorelin. SAHPRA does not publish a searchable, product-level register of Section 21 approvals [5].

Research peptides versus registered medicines

Tesamorelin sold as a research peptide in South Africa is marketed without SAHPRA approval claim. It is not a scheduled substance in the same controlled sense as narcotics. However, its status as an unregistered medicine means any sale or supply for human use as a therapy contravenes the Act, which defines a medicine as any substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans.

Researchers comparing tesamorelin against CJC-1295, or considering tesamorelin alongside a CJC-1295 and Ipamorelin combination pen, face the same regulatory framing: none of these are SAHPRA-registered finished medicines.

JCSG.org carries Body Pharm tesamorelin for South African researchers. The current price and stock status are shown in the buy box at the top of this page.

Disclaimer. Regulatory status verified against publicly available SAHPRA information in May 2026 and is subject to change. Confirm current status directly at sahpra.org.za before relying on any statement in this section. This article is reference material, not medical or legal advice.

Tesamorelin vs CJC-1295: Which GHRH Analogue to Research?

Tesamorelin and CJC-1295 are both synthetic GHRH analogues, but they differ in half-life, evidence base, and regulatory standing.

Tesamorelin is a stabilised 44-amino-acid GHRH(1-44) analogue with a plasma half-life of roughly 0.6–1.1 hours. It is dosed once daily and is the only GHRH analogue with phase 3 RCT evidence and FDA approval (for HIV-associated lipodystrophy) [5].

CJC-1295 is a GHRH(1-29) analogue available in two forms. The unmodified version (often called Mod GRF 1-29) has a roughly 30-minute half-life and requires multiple daily injections because the peptide is rapidly cleaved by dipeptidyl peptidase-4. The DAC-conjugated version binds albumin and extends the effective half-life to approximately 5–8 days [6].

The functional consequence is pulsatile versus quasi-continuous GH exposure. Tesamorelin produces a discrete, physiologically-shaped GH pulse that mimics native GHRH signalling and has documented VAT reduction in HIV lipodystrophy trials. CJC-1295 DAC drives a sustained elevation of GH and IGF-1. Some researchers pair it with a GHRP such as ipamorelin to amplify pulse amplitude. The CJC-1295 and Ipamorelin combination pen is a concrete formulation example of that approach.

Choosing between them in a research context

Tesamorelin has the stronger clinical evidence base, particularly for visceral fat outcomes. CJC-1295 has wider use in non-clinical peptide research communities and lower per-dose frequency in its DAC form, but no comparable RCT body — funding for CJC-1295 trials has been limited compared to tesamorelin's HIV-lipodystrophy programme. Neither holds SAHPRA registration in South Africa as of 2026 [16].

Both are available on JCSG.org. Browse all Body Pharm GHRH peptides.

Frequently Asked Questions About Tesamorelin